Navigation Links
BioRestorative Therapies Announces Next Generation of Stem Cell Disc Delivery Device
Date:5/3/2012

JUPITER, Fla., May 3, 2012 /PRNewswire/ -- BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTCQB: BRTX), a life sciences company focused on adult stem cell-based therapies, announced today that the latest version of its stem cell disc delivery device, which is to be used in the treatment of bulging and herniated discs, has shown improvements when compared to earlier versions.

The first generation of the device had shown the potential to reduce disc bulges and avoid lower back surgery with a simple injection procedure.  The latest generation has shown improvements, and testing of the device will continue to be done to obtain improved disc penetration and steering for optimal cell placement. 

The patent-pending delivery device to be used by medical practitioners is a specifically designed needle/catheter delivery system that will inject cells directly into the annular tear that is causing the bulge or herniation.

On April 11, 2012, the Company announced the closing of its licensing agreement with Regenerative Sciences, Inc. pursuant to which BRT was granted, among other things, the exclusive right to license and sell the stem cell delivery device worldwide.

Mark Weinreb, CEO of BRT, commented, "The delivery device's novel design and unique capability of delivering cells, specifically where they are most effective, is a necessary component of the treatment regimen.  As our disc restoration program advances and we receive all necessary approvals, we look forward to easing the pain experienced by back and disc pain sufferers." 

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc.'s goal is to become a leader in developing medical procedures using cell and tissue protocols, primarily involving a patient's own stem cells (non-embryonic), allowing patients to undergo cellular-based treatments. The Company has obtained a license for the adult stem cell treatments of disc and spine conditions, including bulging and herniated discs. The technology is an advanced stem cell injection procedure, using the patient's own cells, that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the legs and feet.  The Company has also launched a technology that involves the use of a brown fat cell-based therapeutic/aesthetic program, known as the ThermoStem™ Program.  The ThermoStem™ Program will focus on treatments for obesity, weight loss, diabetes, hypertension, other metabolic disorders and cardiac deficiencies and will involve the study of stem cells, several genes, proteins and/or mechanisms that are related to these diseases and disorders. The Company also offers facial creams and products under the Stem Pearls® brand.

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

Investor Contacts:
KCSA Strategic Communications
Philip Carlson / Josh Dver
+1 212.896.1233 / +1 212.896.1239 
pcarlson@kcsa.com / jdver@kcsa.com

 


'/>"/>
SOURCE BioRestorative Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioRestorative Therapies Announces Closing of License Agreement for Adult Stem Cell Disc/Spine Procedure
2. BioRestorative Therapies Obtains $2.1 Million in 2012 Private Financing
3. BioRestorative Therapies Retains KCSA Strategic Communications as Investor Relations Counsel
4. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
5. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
6. BioRestorative Therapies, Inc. Begins Trading Under New Name and Symbol ("BRTX")
7. BioRestorative Therapies, Inc. Announces Upgrade to OTCQB Market
8. Stem Cell Assurance, Inc. Announces Change of Name to BioRestorative Therapies, Inc.
9. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
10. Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
11. Steve Jobs Death Highlights Critical Need for New Therapies for Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Patient Monitoring and Diagnostic ... connectivity to reduce the amount of wiring in a healthcare facility and allow ... devices including infusion pumps, heart and hypertension monitoring, glucose monitoring, and other wearable ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... cells for research and the development of cardiac regeneration therapies. The development ... numbers of cardiomyocytes (hPSC-CMs). Due to varying differentiation efficiencies, further enrichment of ...
(Date:5/23/2017)... ... May 23, 2017 , ... Vortex Biosciences , provider of circulating ... prostate circulating tumor cells using Vortex microfluidic technology ” in Nature Precision Oncology on ... Dr. Dino Di Carlo and Dr. Matthew Rettig at the University of California, Los ...
(Date:5/23/2017)... ... 2017 , ... Cambridge Semantics , the leading provider of Big Data ... Conference and Expo in Boston May 23-25 with a featured speaker and solution ... Data Lake is also a finalist for the Best of Show award. , James ...
Breaking Biology Technology:
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/23/2017)... 2017 Research and Markets has announced the ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... of around 8.8% over the next decade to reach approximately $14.21 ... market estimates and forecasts for all the given segments on global ...
Breaking Biology News(10 mins):